Replies to post #165718 on Biotech Values

[DewDiligence]

Took a while for this program to see the light of day, as long trials are needed for determining efficacy. Thanks for posting this.

The long delay may have been caused in part by controversy within Genentech (see masterlongevity’s comments in #msg-91454309) as well as some lingering resentment of Tanox stemming from an especially nasty litigation over the rights to Xolair (#msg-2517727, #msg-5951137).

In any case, a treatment for dry AMD is a major unmet medical need.

[DewDiligence]

Is this level of efficacy seen (20.4% reduction in GA) clinically meaningful?

I think it is, but others might disagree. A related question is whether it is meaningful from a regulatory standpoint, which is hard to answer because the endpoints required for approval in dry AMD are not as well established as in wet AMD.